Arcus Biosciences (RCUS) Other Non-Current Assets (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Other Non-Current Assets of $61.0 million for Q1 2026, down 14.08% year-over-year from $71.0 million in Q1 2025, and down 3.17% quarter-over-quarter from $63.0 million in Q4 2025.
Arcus Biosciences (RCUS) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Arcus Biosciences' Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $61.0 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 14.08% year-over-year to $61.0 million; the TTM figure through Mar 2026 stood at $61.0 million (down 14.08% YoY), while the FY2025 annual figure was $63.0 million, down 13.7% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $61.0 million, down from $63.0 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $114.0 million in Q4 2022, with the low at $3.0 million in Q2 2022.
- The 5-year median for Other Non-Current Assets is $71.0 million (2025), against an average of $64.5 million.
- Peak annual rise in Other Non-Current Assets reached 3527.29% in 2023, while the deepest fall reached 94.74% in 2023.
- Arcus Biosciences' Other Non-Current Assets stood at $114.0 million in 2022, then tumbled by 94.74% to $6.0 million in 2023, then jumped by 1116.67% to $73.0 million in 2024, then retreated by 13.7% to $63.0 million in 2025, then slipped by 3.17% to $61.0 million in 2026.
- Business Quant data shows RCUS's Other Non-Current Assets at $61.0 million in Q1 2026, $63.0 million in Q4 2025, and $65.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | 59.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.00 Mn |
| Mar 31, 2026 | 61.00 Mn |
| Dec 31, 2025 | 63.00 Mn |
| Sep 30, 2025 | 65.00 Mn |
| Jun 30, 2025 | 69.00 Mn |
| Mar 31, 2025 | 71.00 Mn |
| Dec 31, 2024 | 73.00 Mn |
| Sep 30, 2024 | 75.00 Mn |
| Jun 30, 2024 | 75.00 Mn |
| Mar 31, 2024 | 78.00 Mn |
| Dec 31, 2023 | 6.00 Mn |
| Sep 30, 2023 | 108.00 Mn |
| Jun 30, 2023 | 109.00 Mn |
| Mar 31, 2023 | 112.00 Mn |
| Dec 31, 2022 | 114.00 Mn |
| Sep 30, 2022 | 3.01 Mn |
| Jun 30, 2022 | 3.01 Mn |
| Mar 31, 2022 | 10.89 Mn |
| Dec 31, 2021 | 116.00 Mn |
| Sep 30, 2021 | 3.01 Mn |